Comparative effectiveness for early-stage NSCLC without lymph node involvement based on prospective studies

These findings suggest the combination of systemic therapies, such as surgery plus ATKI or SBRT plus immunotherapy, superior approaches for patients with eNSCLC-N0 depending on the genomic mutation status and patient tolerability.